Table 4.
Assay quantitative read-out among well characterised groups of participants.
| Gene Marker | ATB | ORDS | LTBI | HC | ||||
|---|---|---|---|---|---|---|---|---|
| Cq | Copies/µl | Cq | Copies/µl | Cq | Copies/µl | Cq | Copies/µl | |
| ACTB | 15.9 [15.3–16.8] | 226,500 [129000.0–349500.0] | 16.7 [16.2–17.4] | 135250.0 [86612.5–192250.0] | 17.8 [16.9–18.2] | 67,050 [51100–120750] | 16.5 [16.1–17.0] | 152500.0 [116500.0–199000.0] |
| ARG1 | 23.1 [22.1–23.9] | 6180.0 [3710.0–11400.0] | 24.0 [22.5–24.9] | 3325.0 [ 1926.3–8793.8] | 24.9 [24.2–25.7] | 1952.5 [1146.3–2893.8] | 24.1 [23.6–24.8] | 3265.0 [2050.0–4260.0] |
| ASUN | 26.7 [26.1–27.1] | 846.0 [622.5–1242.5] | 27.1 [26.6–27.7] | 603.8 [419.5–869.3] | 27.9 [26.7–28.5] | 364.8 [237.4–803.6] | 26.6 [26.0–26.8] | 902.5 [772.0–1390.0] |
| BATF2 | 21.3 [20.7–22.8] | 21950.0 [8210.0–33850.0] | 25.4 [23.7–26.6] | 1335.0 [585.0–4340.0] | 26.4 [25.2–27.4] | 688.3 [321.1–1525.0] | 26.0 [24.9–27.0] | 886.8 [439.1–1778.8] |
| C1QB | 24.7 [24.2–25.9] | 2190.0 [992.5–3190.0] | 28.5 [27.3–29.5] | 175.0 [94.0–396.3] | 30.3 [28.8–31.2] | 56.0 [29.3–144] | 28.8 [27.6–29.5] | 149.5 [91.9–325.0] |
| CD64 | 19.0 [18.0–19.5] | 12700.0 [9020.0–24600.0] | 21.9 [21.0–23.0] | 1842.5 [871.8–3203.8] | 23.3 [22.3–23.8] | 691.8 [502.6–1402.5] | 22.9 [22.3–23.2] | 949.5 [774.0–1355.0] |
| DHX29 | 26.0 [25.4–26.4] | 918.0 [694.0–1355.0] | 26.7 [26.3–27.4] | 560.0 [360.9–760.9] | 27.2 [26.4–27.9] | 407.8 [263.5–706.6] | 26.4 [26.0–27.1] | 719.0 [448.0–898.0] |
| DUSP3 | 26.1 [25.4–26.7] | 442.5 [294.0–730.5] | 28.0 [27.2–28.8] | 133.3 [75.3–215.3] | 29.2 [28.7–29.8] | 58.7 [38.9–83.2] | 28.2 [27.8–28.6] | 110.5 [86.5–151.5] |
| GAS6 | 28.3 [27.6–29.1] | 394.5 [245.0 -652.0] | 30.2 [29.3–30.9] | 119.9 [78.0–204.0] | 30.9 [29.8–31.7] | 69.4 [40.1–154.9] | 30.3 [29.8–30.8] | 108.8 [76.8–153.9] |
| GBP5 | 19.7 [18.9–20.9] | 9920 [4255.0–18150.0] | 22.6 [21.7–23.2] | 1312.5 [825.0–2493.8] | 23.1 [22.9–24.3] | 878 [371.3–1052] | 22.7 [22.2–23.0] | 1195.5 [928.5–1635.0] |
| GBP6 | 25.4 [24.5–26.3] | 1085.0 [656.5–1990.0] | 27.5 [26.7–28.5] | 276.8 [144.7–484.6] | 28.4 [27.2–29.1] | 155.5 [104.8–372.4] | 27.4 [26.5–27.8] | 332.0 [239.0–533.5] |
| KLF2 | 21.7 [20.7–22.4] | 34350.0 [22500.0–67700.0] | 21.9 [21.5–22.6] | 29,500 [19387.5–38175.0] | 22.7 [21.8–23.2] | 18,625 [12907.5–32112.5] | 21.7 [21.3–22.1] | 35650.0 [26050.0–44250.0] |
| NEMF | 21.9 [21.2–22.2] | 7710.0 [5950.0–11750.0] | 22.4 [21.9–22.9] | 5537.5 [3765.0–7436.3] | 23.0 [22.2–23.4] | 3577.5 [2806.3–6186.3] | 21.8 [21.1–22.3] | 7780.0 [5650.0–12650.0] |
| PTPRC | 21.6 [20.9–22.0] | 16600.0 [12600.0–28450.0] | 21.3 [20.8–22.0] | 20375.0 [12500.0–30037.5] | 21.7 [21.2–22.2] | 16,350 [10830–22600] | 20.8 [20.4–21.4] | 30100.0 [19000.0–38450.0] |
| SEPT4 | 33.2 [31.9–36.0] | 6.0 [1.0–12.4] | 34.8 [32.9–35.9] | 3.1 [0.8–10.0] | 34.3 [33.3–35.9] | 2.1 [0.6–4.9] | 33.3 [32.3–35.0] | 5.0 [1.7–8.9] |
| ZNF296 | 25.4 [24.7–26.3] | 460.0 [247.0–740.0] | 25.6 [25.1–26.3] | 411.0 [255.5–565.6] | 26.0 [25.5–26.9] | 310.5 [172.5–416.0] | 25.2 [24.7–25.5] | 535.0 [423.0–709.0] |
*All data is reported as median quantified level with IQR for each gene marker within each characterized group of participants.